EXCLUSIVE Illumina in talks with EU regulators to divest Grail - sources
BRUSSELS, Sept 5 (Reuters) - U.S. life sciences company Illumina (ILMN.O) is in talks with European Union antitrust regulators to divest Grail (GRAL.O) ahead of an expected EU veto next week of its $7.1 billion acquisition of the biotechnology company, people familiar with the matter said.
The European Commission is set to block the deal because remedies offered by Illumina do not fully address the EU competition enforcer's concerns, other sources told Reuters last month. read more
Illumina completed its takeover of Grail in August last year without waiting for the EU green light, and was subsequently ordered by the EU watchdog to keep Grail separate and install independent managers to run the company until a regulatory decision on the deal. read more
The Commission, which is scheduled to decide on the takeover by Sept. 12, declined to comment. Illumina had no immediate comment.
Illumina has offered royalty-free global licences for some patents to rivals and a three-year patent truce with Chinese rival BGI in Europe in a bid to address EU antitrust worries, according to other people familiar with the matter.
Illumina won the backing of a U.S. administrative judge last week who rejected a lawsuit by the Federal Trade Commission (FTC) against the deal. The FTC will appeal the ruling. read more
The court judgment does not have any impact on the EU decision, the people said.
Our Standards: The Thomson Reuters Trust Principles.
- BusinessActivist fund Enkraft presses renewables firm ABO Wind for clearer strategy
Activist fund Enkraft, which owns stakes in several German energy firms, has criticised renewables group ABO Wind , claiming the group failed to provide investors with a clear strategic roadmap.